Clinical trials: Respiratory Disorder
Non-Small-Cell Lung Carcinoma
A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy
The main purpose of this study is to determine whether nivolumab + chemotherapy is effective as compared to chemotherapy in the treatment of patients with EGFR mutation, NSCLC who failed first line (1L) or second-line (2L) EGFR…
- Trial name
- CheckMate722 (NCT02864251)
- Testing
- Nivolumab, Ipilimumab, Pemetrexed
- Where
- 109 sites in United States, Canada and 8 more
- Volunteers
- 367 people
- Sponsor
- Bristol-Myers Squibb
Covid19
Expanded Access to T89 for Treatment Use in Intermediate-size Patients Population With COVID-19
This expanded access use program will provide a botanical drug of T89 for treatment use in an intermediate-size population infected with SARS-CoV-2 who have severe COVID-19, or who are judged by a healthcare provider to be at…
- Trial name
- NCT04646031
- Testing
- T89 capsule
- Where
- United States
- Sponsor
- Tasly Pharmaceuticals, Inc.
Alpha 1-Antitrypsin Deficiency, Emphysema
Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema
Phase 2 study to compare SAR447537 (INBRX-101) to plasma derived A1PI therapy in adults with AATD emphysema
- Trial name
- ELEVAATE (NCT05856331)
- Testing
- SAR447537, Zemaira
- Where
- 65 sites in United States, Australia and 6 more
- Volunteers
- 99 people
- Sponsor
- Sanofi
COVID-19 Pneumonia, Impaired Respiratory Function
Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia
This clinical study was designed to assess the efficacy and safety of DFV890 for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infected patients with coronavirus disease 2019 (COVID-19) pneumonia…
- Trial name
- NCT04382053
- Testing
- DFV890, Standard of Care (SoC)
- Where
- 29 sites in Argentina, Brazil and 10 more
- Volunteers
- 143 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Neoplasms, Solid Tumors
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
This study is open to adults with advanced cancer in the biliary tract, pancreas, lung, or bladder. This is a study for people for whom previous treatment was not successful or no treatment exists.
- Conditions
- Pancreatic Neoplasms, Solid Tumors, Biliary Tract Cancer, Lung Neoplasms
- Trial name
- NCT05512377
- Testing
- Brigimadlin
- Where
- 60 sites in United States, Australia and 14 more
- Volunteers
- 99 people
- Sponsor
- Boehringer Ingelheim
Influenza, Human
A Study to Assess the Safety and Immune Response of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India
The purpose of this study is to gather additional evidence of the safety and immunogenicity of 1 dose of Fluarix Tetra (0.5 milliliter [mL]) (Northern Hemisphere (NH)2023-2024) in individuals aged 65 years and above to fulfill a…
- Trial name
- NCT05648357
- Testing
- Fluarix Tetra Vaccine
- Where
- 6 sites in India
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Allergic Rhinitis, Allergy
Phase I/IIa Clinical Evaluation of AllerT vs Placebo in Subjects Allergic to Birch Pollen
Birch pollen allergic patients are currently treated by subcutaneous injections of pollen extracts either by standard allergen specific immunotherapy (SIT) or ultra-rush immunotherapy.
- Trial name
- AN003 (NCT01728519)
- Testing
- AllerT SC, AllerT ID
- Where
- Switzerland
- Volunteers
- 29 people
- Sponsor
- Anergis
Pulmonary Disease, Chronic Obstructive
Change in Symptom and Quality of Life in COPD by Budesonide/Glycopyrronium/Formoterol Fumarate Pressurized Metered Dose Inhaler (BGF pMDI)
This study is primarily aimed to investigate whether PROs can be improved after the initiation of BGF pMDI in real world clinical settings.
- Trial name
- EBISU (NCT05219630)
- Where
- 17 sites in Japan
- Volunteers
- 106 people
- Sponsor
- AstraZeneca
COVID-19
A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients
The purpose of this study is to assess the efficacy and safety of Proxalutamide (GT0918) in male outpatients with mild to moderate COVID-19 disease
- Trial name
- NCT04869228
- Where
- Brazil
- Volunteers
- 380 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Lung Cancer, Nodes, Lung
Confirmation of Accuracy of the Tool-in-lesion Technology (TiLT) of the Galaxy System With Integrated TOMO Technology
This study will evaluate the feasibility of performing robotic navigation of peripheral airways in human subjects for the purpose of biopsying peripheral lung lesions.
- Trial name
- TiLT (NCT06056128)
- Testing
- Robotic assisted bronchoscopy
- Where
- Hong Kong
- Volunteers
- 25 people
- Sponsor
- Noah Medical
Seasonal Allergic Rhinitis
A Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis (MK-0476-192)(COMPLETED)
A study of the ability of montelukast to improve signs and symptoms of seasonal allergic rhinitis compared with placebo. Loratadine is included in the study as an active control.
- Trial name
- NCT00960141
- Testing
- montelukast sodium, Comparator: loratadine
- Volunteers
- 829 people
- Sponsor
- Organon and Co
Pulmonary Disease, Chronic Obstructive
Post-marketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease
Study to obtain further information on the tolerability and efficacy of Atrovent® inhalets in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice
- Trial name
- NCT02233881
- Testing
- Atrovent® - inhalets
- Volunteers
- 4,222 people
- Sponsor
- Boehringer Ingelheim
Lung Neoplasms
Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung Cancer
Primary Objective: Response rate (by contrast CT scan) Secondary Objectives: Progression-free survival (PFS) Overall survival (OS)
- Trial name
- C-CRISP (NCT01266512)
- Testing
- DOCETAXEL, Intensity Modulated Radiotherapy (IMRT), CISPLATIN
- Where
- Hong Kong
- Volunteers
- 34 people
- Sponsor
- Sanofi
Pulmonary Disease, Chronic Obstructive
Effect of Spiriva on the Activities of Daily Living Score Recommended in Austrian COPD Guidelines
The primary goal of this post marketing surveillance (PMS) study is to document the efficacy of Tiotropium (Spiriva) to improve physical activity measured by a score that is recommended in national chronic obstructive pulmonary…
- Trial name
- NCT00615992
- Testing
- Tiotropium
- Where
- 73 sites in Austria
- Volunteers
- 754 people
- Sponsor
- Boehringer Ingelheim
Influenza
Observational Study on the Pharmacokinetics of Oseltamivir in the Treatment of Influenza During Lactation
The main purpose of this study is to assess the potential exposure of neonates to oseltamivir during lactation by examining oseltamivir concentrations in maternal blood, urine, and breast milk in breastfeeding women who are…
- Trial name
- NCT01130636
- Testing
- Oseltamivir
- Where
- 2 sites in Hungary
- Volunteers
- 6 people
- Sponsor
- Pharmahungary Group
Hepatitis B, Polio
Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV
The purpose of this study is to document the immunological response to the investigational hexavalent vaccine at the 6, 10, and 14 weeks schedule The primary objective is to demonstrate that the hexavalent DTaP-IPV-HB-PRP~T…
- Conditions
- Hepatitis B, Polio, Diphtheria, Pertussis
- Trial name
- NCT00362336
- Testing
- DTaP-IPV-HB-PRP~T, CombAct-HIB®, Engerix B® Pediatric
- Where
- 2 sites in South Africa
- Volunteers
- 622 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
COVID-19
To Evaluate Safety and Immunogenicity of a Prophylactic Plasmid DNA
Currently, several vaccines are available to combat the COVID-19 pandemic. The persistence of SARS-CoV-2 globally requires the development of additional vaccines to aid in preventing further SARS-CoV-2 infections.
- Trial name
- VAX-002-01 (NCT06436911)
- Testing
- COVIGENIX VAX- 002
- Where
- 6 sites in Canada
- Volunteers
- 46 people
- Sponsor
- Entos Pharmaceuticals Inc.
Tonsillitis
Efficacy Study of Pristinamycin Versus Amoxicillin to Treat Tonsillitis Induced by Streptococcus in Children
The primary objective of this study is to demonstrate the non-inferiority, at the assessment visit (V3 (D10/D14)), in terms of bacteriological efficacy of pristinamycin (PRI) administered for 4 days versus amoxicillin (AMX)…
- Trial name
- PRI-angine (NCT00393744)
- Testing
- pristinamycin, amoxicillin
- Where
- France
- Volunteers
- 395 people
- Sponsor
- Sanofi
NSCLC Stage IV
MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC
Assess the Efficacy and Safety of MYL-1402O Compared with Avastin®, in the First-line Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer
- Trial name
- NCT04633564
- Testing
- Bevacizumab as MYL-1402O, Bevacizumab as Avastin
- Where
- 102 sites in Belarus, Bosnia and Herzegovina and 15 more
- Volunteers
- 671 people
- Sponsor
- Mylan Pharmaceuticals Inc
Locally Advanced Lung Cancer; Metastatic Lung Cancer
Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer
This is a Phase II, open-label, 4-cohort study of the monoclonal antibody BGB-A317 in combination with standard platinum-based chemotherapy in participants with advanced NSCLC or SCLC.
- Trial name
- NCT03432598
- Testing
- Tislelizumab, Paclitaxel, Gemcitabine
- Where
- 7 sites in China
- Volunteers
- 54 people
- Sponsor
- BeiGene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.